The clinical research market in Poland has experienced remarkable growth, expanding from an estimated €200 million a decade ago to approximately €1.5 billion today. If current projections hold through 2030, the market could reach nearly €4.9 billion. This represents a staggering 25-fold increase over almost two decades, highlighting the rapid development of our industry.
Such exponential growth underscores why Poland has become a global hub for clinical trials. During an interview with Marek Klapa on Telewizja Biznesowa, Wojciech Kula discussed what makes the Polish market so attractive—from strong scientific infrastructure and skilled investigators to efficient regulatory processes and competitive costs.
This surge not only signifies a significant achievement for companies like Axcellant but also reflects Poland’s deeper integration into global clinical research networks. If the trajectory continues, the country is poised to play an even more influential role in developing the next generation of therapies.
Watch the full interview (in Polish) here.
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant